Heron Therapeutics Inc Stock Price, News & Analysis

Heron Therapeutics, Inc. (Nasdaq: HRTX) announced that Barry Quart, CEO, and John Poyhonen, President, will engage in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference. The event is scheduled for September 27, 2021, at 1:20 pm ET. A live webcast will be accessible via the company's website, with a replay available for 60 days post-event. Heron Therapeutics focuses on developing advanced treatments to meet significant unmet patient needs in acute care and oncology. For further details, visit www.herontx.com.

Heron Therapeutics (HRTX) reported financial results for Q2 and H1 2021, highlighting a net loss of $61 million and $113.6 million, respectively. Net product sales for oncology care amounted to $22.4 million in Q2, slightly down from $22.7 million a year prior. ZYNRELEF, a new product launched in July 2021, saw positive early adoption with 61 unique accounts placing orders. However, the company faces challenges in growth projections due to reduced cancer patient treatments amid the pandemic and increased competition. Cash reserves stand at $257.7 million, reflecting a strategic preparation for product launches.

Heron Therapeutics, Inc. (Nasdaq: HRTX) announced the publication of HOPE Hernia-1 study results for ZYNRELEF in hernia repair surgery. The study demonstrates over 90% of patients discharged without opioid prescriptions and 95% recovering opioid-free, showcasing ZYNRELEF's role in non-opioid multimodal analgesia. ZYNRELEF is an extended-release formulation of bupivacaine and meloxicam, approved for postsurgical analgesia. The findings emphasize ZYNRELEF’s potential to minimize opioid use, pivotal in addressing the opioid crisis.

Heron Therapeutics (HRTX) announced the online publication of a new analysis in the journal Pain Management, evaluating the effectiveness of ZYNRELEF (bupivacaine and meloxicam) in adults 65 years and older after bunionectomy and hernia repair. The analysis revealed that 58% of bunionectomy and 87% of hernia repair patients did not require opioids post-surgery. ZYNRELEF was well tolerated, showing a similar safety profile to bupivacaine, with no serious adverse events related to the medication. This positions ZYNRELEF as a significant improvement over standard opioid treatments.

Heron Therapeutics announced a contract with Apexus for ZYNRELEF under the 340B Drug Pricing Program, aimed at improving access to this FDA-approved medication for postoperative pain management. ZYNRELEF, a dual-acting local anesthetic, was approved on May 12, 2021, and provides pain relief for up to 72 hours, significantly reducing the need for opioids. This partnership seeks to ensure that discounted pricing is available to healthcare providers, helping to combat the opioid crisis. Over 90,000 opioid overdose deaths were reported in the year ending September 2020, underscoring the importance of ZYNRELEF's wide availability.

Heron Therapeutics, Inc. (Nasdaq: HRTX) has announced the commercial launch of ZYNRELEF, a dual-acting local anesthetic, now available through national wholesalers and specialty distributors in the U.S. Approved by the FDA on May 12, 2021, ZYNRELEF provides postoperative pain relief for up to 72 hours following surgeries like bunionectomy and total knee arthroplasty. The product aims to reduce opioid reliance and has shown significant efficacy in pain management. Heron has secured contracts with major purchasing organizations to enhance market penetration.

Heron Therapeutics (Nasdaq: HRTX) announced that CEO Barry Quart will participate in a fireside chat at the 2021 Jefferies Virtual Healthcare Conference on June 1, 2021, at 11:00 AM PT. A live webcast of the event will be available on the company's website and will be archived for 60 days. Heron Therapeutics focuses on developing innovative treatments for unmet patient needs, especially in acute care and oncology.

Heron Therapeutics (HRTX) has announced a private placement of $150 million in senior unsecured convertible promissory notes, converting at a price of $15.276 per share, a 13% premium. Proceeds will fund the launch of ZYNRELEF, an FDA-approved dual-acting local anesthetic for postoperative pain. The notes accrue 1.5% interest, maturing on June 1, 2026. The company anticipates that these funds will enable ZYNRELEF's launch and help achieve profitability. ZYNRELEF has also received formulary approval shortly after FDA approval.

Heron Therapeutics announced FDA approval of ZYNRELEF (bupivacaine and meloxicam), extending postoperative pain management up to 72 hours after surgeries like bunionectomy and total knee arthroplasty. This first-in-class dual-acting local anesthetic significantly reduces pain and opioid usage, offering a vital alternative amid rising opioid-related deaths. The company plans to leverage its existing commercial team for a robust launch by July 2021, following successful Phase 3 trials that included over 1,000 patients. This approval could reshape the postoperative pain management landscape.